Massimiliano Bonifacio

Author

Also Known As

, Bonifacio, M., Bonifacio, Massimiliano, Gruppo Triveneto LMC, M Bonifacio, M. Bonifacio, Margel C. Bonifacio, MassimiliaNo Bonifacio, Massimiliano Bonifacio

433

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

University of Verona Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Istituti di Ricovero e Cura a Carattere Scientifico University of Padua Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

About

Massimiliano Bonifacio is an author at University of Verona specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	47	2K
2	Health Sciences	15	18	581
3	Engineering	1	1	28
4	Natural Sciences	1	1	15
5	Nursing	1	1	21

Massimiliano Bonifacio

115

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Blood	2018	810
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults Robin Foà, Renato Bassan, Antonella Vitale, New England Journal of Medicine	2020	467
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, Cancer	2019	144
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Cancer	2013	138
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study Wolfgang R. Sperr, Michael Kundi, Iván Álvarez‐Twöse, The Lancet Haematology Mast Cell DisorderClinical EpidemiologyDiagnosisPublic HealthRetrospective Cohort Study	2019	135
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano, The Lancet Haematology Polycythaemia VeraHematologyLow-pv StudyPhase 2Medicine	2021	125
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL Robin Foà, Renato Bassan, Loredana Elia, Journal of Clinical Oncology	2023	122
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels Roberta Zanotti, Carla Lombardo, Giovanni Passalacqua, Journal of Allergy and Clinical Immunology AllergyMast Cell DisorderImmunologyAllergenVenomics	2015	121
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis Maurizio Rossini, Roberta Zanotti, Patrizia Bonadonna, Bone Bone Turnover MarkersBone HealthMast Cell DisorderBone Mineral DensityOsteoporosis	2011	114

Page 1